www.jmscr.igmpublication.org Impact Factor 5.244

Index Copernicus Value: 83.27

ISSN (e)-2347-176x ISSN (p) 2455-0450

crossref DOI: https://dx.doi.org/10.18535/jmscr/v5i1.33



Safety and efficacy of Mifepristone plus Misoprostol in Second Trimester Termination of Pregnancy in Previous CS

Authors

Dr Meenakshi Kumari¹, Dr Krishna Murari², Dr Mamta Kumari³

¹Assistant Prof Department of Obstetrics and Gynecology MGM Medical College and Lionsseva Kendra Hospital Kishanganj Bihar

²Assistant Prof Department of Surgery RIMS Ranchi Jharkhand ³Associate Prof Department of Anatomy MGM Medical College Kishanganj Bihar Corresponding Author

Dr Krishna Murari

Email: drkmurari@gmail.com

ABSTRACT

AIM- The present study was undertaken to evaluate the safety and efficacy of mifepristone and misoprostol for pregnancy termination in mid trimester in women with prior scar of Caesarean section in MGM Medical College and LSK Hospital Kishanganj Bihar.

METHODS: 30 women with previous one cesarean and 13-20 weeks gestation were included. This study was done in women coming for induced abortion in MGM Medical College and LSK Hospital Kishanganj.

RESULTS: There was no case of rupture uterus .All patients aborted within 24 hrs. Most of them needed surgical evacuation for removing placental bits.

CONCLUSION: Use of misoprostol in combination with mifepristone is safe and effective for second trimester abortion in women with previous cesarean.

KEYWORDS- *Misoprostol, Mifepristone, cesarean, rupture uterus.*

INTRODUCTION

As cesarean delivery is becoming very common we are day to day facing the women coming for second trimester abortion with previous cesarean. The past decade has seen India cross the WHO threshold for caesarean deliveries (15%). And still contraceptive methods are not widely practiced. In many cases women conceive during lactational amenorrhea with previous child being less than one year old. As per guidelines of MTP act we can perform abortions up to 20 weeks of gestation. Therefore number of women seeking for second trimester abortion post caesarean is also increasing.

Mifepristone the antiprogestin along with synthetic prostaglandin E1 analogue Misoprostol is being used in medicinal abortion. The aim of this study was to analyze the safety and efficacy of these drugs in second trimester abortion in women with previous cesarean.

METHODS

The present study was in gynecological OPD of MGM Medical College and LSK Hospital, Kishanganj Bihar in women coming for second trimester abortion with previous one cesarean.30 women after proper counselling and taking

JMSCR Vol||05||Issue||01||Page 15395-15397||January

informed consent were enrolled. Duration of study was from 01.02.15 to 01.10.15.

All the women included in the study were healthy with no significant medical problems. The age group was from 25-35 yrs. The indication for termination were in consonance with the MTP act. Ethical clearance was obtained from the hospital ethical committee.

Exclusion criteria

- 1. Women with baseline hemoglobin<8gm/dl
- 2. Bleeding PV at the time of examination
- 3. Women with any type of medical problem and PID
- 4. Multiple pregnancy and missed abortion

METHOD

Women who fulfilled the above criteria and gave the consent in written were included in the trial and were given mifepristone 200mg stat dose and then after 24 hrs. admitted and started on misoprostol 600 mcg per vaginally high in posterior fornix followed by 200 mcg sublingually every four hourly till abortion. Before every next dose, the patient was examined and if the patient was having adequate contractions (3 in 10 minutes) or cervix was dilated (4cm) or complaining of unbearable pain next dose was

deferred. Side effects were recorded. Induction abortion recorded.

All patient was supervised thoroughly with timely recording of vital signs(B.P. Pulse Temperature) Complication of Misoprostol (fever, chills, diarrhea, nausea, vomiting) and signs of uterine rupture (persistent abdominal pain, maternal tachycardia, hypotension, vaginal bleeding).

Following expulsion of fetus Oxytocin infusion was given for 1 hour. Many had incomplete evacuation which was completed surgically under anesthesia.

RESULTS

Table 1 shows complication and side effects among our study group

Side effects	Number of cases	Percentage	
Excessive blood loss	15	5%	
Need analgesia	27	90%	
fever	6	20%	
nausea	12	40%	
Diarrhea	6	20%	
Uterine rupture	0	0%	

27 patient needed analgesia and surgical evacuation. None had rupture uterus 15 cases had excessive blood loss which was managed by packing and caboprost injection no one needed blood transfusion.

Table 2: Induction abortion interval

Weeks	4-6hrs	6-8hrs	8-10hrs	10-12hrs	12-16hrs	16-20hrs	>20hr	Total
12-16	1	11	3	-	2	-	-	17
16-20	-	3	2	2	4	1	1	13

Induction abortion interval was calculated from first dose of misoprostol till expulsion of fetus partially or completely. Only three cases had complete expulsion rest needed surgical exploration. Higher gestation needed higher doses of misoprostol so they suffered more side effects.

DISSCUSION

The aim of our study was to evaluate the safety of combining mifepristone with misoprostol for second trimester abortion in women with previous cesarean. Several studies have shown misoprostol to be a safe agent ^[1,2,3,4]. Our study clearly shows

the above combination is safe and effective in women with previous cesarean. Our study showed no case of rupture uterus similar to many studies ^[1,2,3,4]. Mean induction abortion interval in our study was 10.32+/-2.05 hrs. which is comparable to 12-16 hours in other studies ^[5,6,7,8]. In our study 96.6% women aborted within 20hrs which is comparable to about 90% reported in other studies ^[5,6,7]

Misoprostol can be given orally, sublingually, vaginally or rectally. The tablet is coated with cellulose to make stable at room temperature [9] and this may result in delayed or varying

JMSCR Vol||05||Issue||01||Page 15395-15397||January

absorption or cumulative effect when applied vaginally [9,10].

Nausea was commonest side effect of misoprostol (40%) fever and diarrhea was seen in 20%. As women with previous cesarean are less pain tolerant so they required analgesia more often.

CONCLUSION

Mifepristone and misoprostol when used for second trimester termination in previous cesarean appeared safe and applicable. However larger study would be needed to provide accurate assessment of risk of uterine rupture.

REFERENCES

- ROUZI A.A.: Second-trimester pregnancy termination with misoprostol in women with previous caesarean sections. Int.j. Gynaecol Obstet,80:317_8,2003.
- 2. DEBBY A. GOLAN A, SAVIR R.et al.:Midtrimester abortion in women with previous uterine scar. Eur. J.Obstet. Gynecol. Reprod. Biol. 109:177-8,2003.
- 3. HERABUTYA H., CHANARACHAK-ULB. and PUNYAVACHIRA P.; Induction of labour with vaginal misoprostol for second trimester termination of pregnancy in scarred uterus. Int. j.Gynaecol. Obstet., 83:297-7 2003
- 4. DAPTONE A., NZEWENGAB G. and KONSTANTINOS D et al .The use of vaginal misoprostol for second trimester termination of pregnancy with previous single caesarean section, contraception, 74:324-7,2006
- 5. JAIN JK, MSSHELL DR JR.: A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second trimester pregnancy. N Engl J Med 1994;331:290-3.
- DICKINSON JE, EVANS SF. Acomparison of oral misoprostol with vaginal misoprostol administrasion in second trimester pregnancy termination for fetal

- abnormality, ObstetGynecol 2003;101: 1294-9.
- 7. JAIN JK, KUO J, MISHELL DR JR. Comparison of two doing regimens of intravaginal misoprostol for second trimester pregnancy termination. ObstetGynecol 1999;93:571-5.
- 8. DICKINSON JE .Misoprostol for second trimester pregnancy termination in women with prior caesarean delivery. Obstet Gynaecol 2005,105:352-6
- 9. COLLINS P.W., PAPPO R. and DAJANI E.Z.: Chemistry and synthetic development of misoprostol .Dig. Dis .Sci, 30(11 suppl):1145-75,1985.
- 10. WING D.A., JONES M.M., RAHALL A., GOODWIN T.M. and PAUL R.H.: Acomparison of misoprostol and prostaglandin E2 gel for preinduction cervical ripening and labour induction .Am. J. Obstet Gynecol., 172:1811-6,1995.